Avobenzone,homosalate,octisalate,octocrylene Cream
NDC Package 49527-910-00

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Avobenzone, Homosalate, Octisalate, Octocrylene cream is a drug for further processing. This formulation utilizes a cream delivery system. Marketed by Clinique Laboratories Llc, this product is identified by NDC 49527-910.

Identification & Billing

NDC Package Code
49527-910-00
Package Description
200 kg in 1 DRUM
Product Code
49527-910
11-Digit Billing Format
49527091000

Clinical Specifications

Proprietary Name
Avobenzone, Homosalate, Octisalate, Octocrylene
Non-Proprietary Name
Avobenzone, Homosalate, Octisalate, Octocrylene
Substance Name
Avobenzone; Homosalate; Octisalate; Octocrylene
Dosage Form
Cream - An emulsion, semisolid3 dosage form, usually containing > 20% water and volatiles5 and/or < 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Active Ingredient(s)

Regulatory & Marketing

Labeler Name
Clinique Laboratories Llc
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
05-21-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49527-910-00 identifies a specific commercial package of 200 kg in 1 drum of Avobenzone, Homosalate, Octisalate, Octocrylene (UNFINISHED drug), drug for further processing labeled by Clinique Laboratories Llc. This cream is formulated for use and contains avobenzone; homosalate; octisalate; octocrylene as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Clinique Laboratories Llc on May 21, 2025. The current certification is valid through December 31, 2026.

How is this Clinique Laboratories Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49527091000. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49527-910-00
11-Digit CMS (5-4-2)
49527-0910-00

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.